Blood test could guide anal cancer treatment, reducing side effects
NCT ID NCT07425054
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a blood test (ctDNA) can help doctors customize the dose of chemoradiation for people with anal cancer. Depending on how the tumor responds, some patients may get a lower radiation dose to reduce side effects, while others may get a higher dose or an added immunotherapy drug (Retifanlimab) to improve effectiveness. The goal is to increase survival and reduce unnecessary side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Retifanlimab (also known as ZYNYZ) is an immunotherapy drug that may be added for patients whose cancer does not respond well to chemoradiation.
What this could lead to
If successful, this approach could lead to more personalized and effective treatment for anal cancer, potentially improving survival and reducing side effects by tailoring radiation doses.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 33 participants, so results may not apply to everyone. The ctDNA test is still experimental, and adding Retifanlimab may cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Center
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
NOT_YET_RECRUITINGCleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••